Jessica L Reed1, Allison C Nugent2, Maura L Furey3, Joanna E Szczepanik2, Jennifer W Evans2, Carlos A Zarate2. 1. Section on Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. Electronic address: jessica.reed2@nih.gov. 2. Section on Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland. 3. Section on Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; Janssen Pharmaceuticals of Johnson & Johnson, San Diego, California.
Abstract
BACKGROUND: In the search for novel treatments for depression, ketamine has emerged as a unique agent with rapid antidepressant effects. Experimental tasks involving emotional processing can be used during functional magnetic resonance imaging scanning to investigate ketamine's effects on brain function in major depressive disorder (MDD). This study examined ketamine's effects on functional magnetic resonance imaging activity during an emotional processing task. METHODS: A total of 33 individuals with treatment-resistant MDD and 24 healthy control participants (HCs) took part in this double-blind, placebo-controlled crossover study. Participants received ketamine and placebo infusions 2 weeks apart, and functional magnetic resonance imaging scans were conducted at baseline and 2 days after each infusion. Blood oxygen level-dependent signal was measured during an emotional processing task, and a linear mixed-effects model was used to analyze differences in activation among group, drug, and task-specific factors. RESULTS: A group-by-drug interaction was observed in several brain regions, including a right frontal cluster extending into the anterior cingulate cortex and insula. Participants with MDD had greater activity than HCs after placebo infusion but showed lower activity after ketamine infusion, which was similar to the activity in HCs after placebo. A group-by-drug-by-task condition interaction was also found, which showed further differences that varied between implicit and explicit emotional conditions. CONCLUSIONS: The main results indicate that ketamine had differential effects on brain activity in participants with MDD versus HCs. The pattern of activation in participants with MDD afterketamine infusion resembled the activation in HCs after placebo infusion, suggesting a normalization of function during emotional processing. The findings contribute to a better understanding of ketamine's actions in the brain. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: In the search for novel treatments for depression, ketamine has emerged as a unique agent with rapid antidepressant effects. Experimental tasks involving emotional processing can be used during functional magnetic resonance imaging scanning to investigate ketamine's effects on brain function in major depressive disorder (MDD). This study examined ketamine's effects on functional magnetic resonance imaging activity during an emotional processing task. METHODS: A total of 33 individuals with treatment-resistant MDD and 24 healthy control participants (HCs) took part in this double-blind, placebo-controlled crossover study. Participants received ketamine and placebo infusions 2 weeks apart, and functional magnetic resonance imaging scans were conducted at baseline and 2 days after each infusion. Blood oxygen level-dependent signal was measured during an emotional processing task, and a linear mixed-effects model was used to analyze differences in activation among group, drug, and task-specific factors. RESULTS: A group-by-drug interaction was observed in several brain regions, including a right frontal cluster extending into the anterior cingulate cortex and insula. Participants with MDD had greater activity than HCs after placebo infusion but showed lower activity after ketamine infusion, which was similar to the activity in HCs after placebo. A group-by-drug-by-task condition interaction was also found, which showed further differences that varied between implicit and explicit emotional conditions. CONCLUSIONS: The main results indicate that ketamine had differential effects on brain activity in participants with MDD versus HCs. The pattern of activation in participants with MDD after ketamine infusion resembled the activation in HCs after placebo infusion, suggesting a normalization of function during emotional processing. The findings contribute to a better understanding of ketamine's actions in the brain. Published by Elsevier Inc.
Entities:
Keywords:
Brain activity; Depression; Emotion; Face processing; Ketamine; fMRI
Authors: Jaskaran B Singh; Maggie Fedgchin; Ella J Daly; Peter De Boer; Kimberly Cooper; Pilar Lim; Christine Pinter; James W Murrough; Gerard Sanacora; Richard C Shelton; Benji Kurian; Andrew Winokur; Maurizio Fava; Husseini Manji; Wayne C Drevets; Luc Van Nueten Journal: Am J Psychiatry Date: 2016-04-08 Impact factor: 18.112
Authors: Teresa A Victor; Maura L Furey; Stephen J Fromm; Arne Öhman; Wayne C Drevets Journal: Int J Neuropsychopharmacol Date: 2013-07-01 Impact factor: 5.176
Authors: Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji Journal: Arch Gen Psychiatry Date: 2006-08
Authors: Nynke A Groenewold; Esther M Opmeer; Peter de Jonge; André Aleman; Sergi G Costafreda Journal: Neurosci Biobehav Rev Date: 2012-12-01 Impact factor: 8.989
Authors: Jennifer W Evans; Joanna Szczepanik; Nancy Brutsché; Lawrence T Park; Allison C Nugent; Carlos A Zarate Journal: Biol Psychiatry Date: 2018-02-15 Impact factor: 13.382
Authors: Teresa A Victor; Maura L Furey; Stephen J Fromm; Patrick S F Bellgowan; Arne Öhman; Wayne C Drevets Journal: PLoS One Date: 2012-10-08 Impact factor: 3.240
Authors: Jessica L Reed; Allison C Nugent; Maura L Furey; Joanna E Szczepanik; Jennifer W Evans; Carlos A Zarate Journal: Neuroimage Clin Date: 2018-07-05 Impact factor: 4.881
Authors: Sara Gonzalez; Megha Vasavada; Stephanie Njau; Ashish K Sahib; Randall Espinoza; Katherine L Narr; Amber M Leaver Journal: Neurol Psychiatry Brain Res Date: 2020-08-28
Authors: Christoph Kraus; Anahit Mkrtchian; Bashkim Kadriu; Allison C Nugent; Carlos A Zarate; Jennifer W Evans Journal: Neuropsychopharmacology Date: 2020-01-29 Impact factor: 7.853
Authors: Nancy B Lundin; Linnea Sepe-Forrest; Jessica R Gilbert; Frederick W Carver; Maura L Furey; Carlos A Zarate; Allison C Nugent Journal: J Affect Disord Date: 2020-10-07 Impact factor: 4.839
Authors: Michelle Thai; Zeynep Başgöze; Bonnie Klimes-Dougan; Bryon A Mueller; Mark Fiecas; Kelvin O Lim; C Sophia Albott; Kathryn R Cullen Journal: Front Psychiatry Date: 2020-08-18 Impact factor: 4.157
Authors: Ashish K Sahib; Joana Ra Loureiro; Megha M Vasavada; Antoni Kubicki; Benjamin Wade; Shantanu H Joshi; Roger P Woods; Eliza Congdon; Randall Espinoza; Katherine L Narr Journal: Transl Psychiatry Date: 2020-07-30 Impact factor: 7.989
Authors: Joana R A Loureiro; Amber Leaver; Megha Vasavada; Ashish K Sahib; Antoni Kubicki; Shantanu Joshi; Roger P Woods; Benjamin Wade; Eliza Congdon; Randall Espinoza; Katherine L Narr Journal: Hum Brain Mapp Date: 2020-03-01 Impact factor: 5.399